Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 1, 2014, Pages 5-17

  Arunesh, Gubbi M ^a   Shanthi, Ekambaram ^a   Krishna, Mudeenahally H ^a   Sooriya Kumar, Jegatheesan ^a   Viswanadhan, Vellarkad N ^a  

^a JUBILANT BIOSYS LTD   (India)

Author keywords

Cancer; Hematological; PIM1; Serine threonine kinase; Solid tumors

Indexed keywords

1 (4 AMINO CYCLOHEXYL) 8 METHYLSULFANYL 1H 1,2,7,9 TETRAAZA CYCLOPENTA[A]NAPHTHALENE 3 CARBOXYLIC ACID AMIDE; 1 (4 AMINO CYCLOHEXYL) 8 METHYLSULFANYL 1H 1,7,9 TRIAZA CYCLOPENTA[A]NAPHTHALENE 3 CARBOXYLIC ACID AMIDE; 3 [1 [5 [3 (4 METHYL [1,4]DIAZEPANE 1 CARBONYL) PHENYL] FURAN 2 YL] METH YLIDENE] 1,3 DIHYDRO INDOL 2 ONE; 3 [1 [7 CYCLOPROPYLAMINO 5 1 PHENYL ETHYLAMINO) PYRAZOLO[1,5 A]PYRIMIDIN 3 YL] METH YLIDENE] PYRROLIDINE 2,5 DIONE; 3 [5 [2 OXO 1,2 DIHYDRO INDOL YLIDENE METHYL] FURAN 2 YL] N (2 PYRROLIDIN 1 YL ETHYL) BENZAMIDE; 4 [6 (4 FLUORO BENZYLAMINO) IMIDAZO[1,2 B]PYRIDAZIN 3 YL] PHENOL; 5 (2 METHYLSULFANYL PYRIMIDIN 4 YL) 1 PIPERIDIN 4 YL 1H PYRAZOLE 3 CARBOXYLIC ACID AMIDE; 5 (2,9 DIAZA SPIRO[5.5]UNDEC 2 YL) 6 METHYL 3 (2 TRIFLUOROMETHYL PYRIDIN 4 YL) 7,8 DIHYDRO 6H 9 OXA 1,2,3A,4,6 PENTAAZACYCLOPEN TA[A]NAPHTHALENE; 5 [1 (2 OXO 1,2 DIHYDRO PYRIDIN 4 YL) METH YLIDENE] THIAZOLIDINE 2,4 DIONE; 5 [1 [2 (3 DIMETHYLAMINO PYRROLIDIN 1 YL) 3 METHOXY PHENYL] METH YLIDENE] THIAZOLIDINE 2,4 DIONE; 5 [1 [5 [3 (2 METHYL IMIDAZOL 1 YL)PHENYLAMINO] PYRAZOLO[1,5 A]PYRIMIDIN 3 YL] METH YLIDENE] THIAZOLIDINE 2,4 DIONE; 5 [1 [5 [3 (4 METHYL [1,4]DIAZEPANE 1 CARBONYL) PHENYL] FURAN 2 YL]METHYLIDENE] 2 THIOXO THIAZOLIDIN 4 ONE; 6' BROMO 2,3' BIINDOLE 2',3(1H,1'H) DIONE 3 OXIME; 7 [6 METHYL 3 (3 TRIFLUOROMETHOXY PHENYL) 7,8 DIHYDRO 6H 9 OXA 1,3A,4,6 TETRAAZACYCLOPENTA[A]NAPHTHALEN 5 YL] 7 AZA SPIRO[3.5]NON 2 YLAMINE; 7' BROMO 2,3' BIINDOLE 2',3(1H,1'H) DIONE 3 OXIME; [1,2,4]TRIAZOLO[4,3 A]PYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; ETP 39010; IMIDAZO[1,2 B]PYRIDAZINE; N [2 (6 BUTYL 7,8 DIHYDRO 6H 9 OXA-1,2,3A,4,6 PENTAAZA CYCLOPENTA[A]NAP HTHALEN 3 YL) QUINOLIN 8 YL] CYCLOHEXANE 1,4 DIAMINE; N [5 (3 TRIFLUOROMETHYL PHENYL) IMIDAZO [2,1 B][1,3,4]THIADIAZOL 2 YL] CYCLOHEXANE 1,4 DIAMINE; PIM 1 KINASE INHIBITOR; PROTEIN KINASE PIM 1; PYRAZOLO [1,5 A]PYRIMIDINE; PYRAZOLO [1,5 A]QUINAZOLIN; PYRROLO[1,2 A]QUINOXALINE DERIVATIVE; SGI 1776; SGI 9481; THIENO[3,2C]QUINOLINE DERIVATIVE; TP 3654; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; HUMAN; IC 50; MEDICAL LITERATURE; PATENT; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG DESIGN; HUMANS; LEGISLATION, DRUG; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-PIM-1; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84890409496     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.848196     Document Type: Review

References (83)

1. Bachmann M, Moroy T. The serine/ threonine kinase Pim-1. Int J Biochem Cell Biol 2005;37:726-30
2. Blanco-Aparicio C, Carnero A. Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities. Biochem Pharmacol 2013;85:629-43
3. Jason MF, Yong X, Anna S, et al. Second generation PIM inhibitor exhibits potent activity in tumor models. Tolero Pharmaceuticals, Inc., Salt Lake City, UT USA .
4. Brault L, Gasser C, Bracher F, et al. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 2010;95:1004-15
5. Sliman F, Blairvacq M, Durieu E, et al. Identification and structure-Activity relationship of 8-hydroxy-quinoline-7- carboxylic acid derivatives as inhibitors of PIM1 kinase. Bioorg Med Chem Lett 2010;20:2801-5
6. Magnuson NS, Wang Z, Ding G, et al. Why target PIM1 for cancer diagnosis and treatment? Future Oncol 2010;6:1461-78
7. Nawijn MC, Alendar A, Berns A. For better or for worse: The role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011;11:23-34
8. Chang M, Kanwar N, Feng E, et al. PIM kinase inhibitors downregulate STAT3Tyr705 phosphorylation. Mol Cancer Ther 2010;9:2478-87
9. Li YY, Popivanova BK, Nagai Y, et al. Pim-3, a proto-oncogene with serine/ threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 2006;66:6741-7
10. Siu A, Virtanen C, Jongstra J. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells. Oncotarget 2011;2:1134-44
11. Blanco-Aparicio C, Collazo AM, Oyarzabal J, et al. Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Lett 2011;300:145-53
12. Macdonald A, Campbell DG, Toth R, et al. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol 2006;7:1
13. Pierre F, Stefan E, Nedellec AS, et al. 7-(4H-1,2,4-Triazol-3-yl)benzo[c] [2,6] naphthyridines: A novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett 2011;21:6687-92
14. Nakano H, Saito N, Parker L, et al. Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound. J Med Chem 2012;55:5151-64
15. Schenone S, Tintori C, Botta M. Using insights into Pim1 structure to design new anticancer drugs. Curr Pharm Des 2010;16:3964-78
16. Qian KC, Wang L, Hickey ER, et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human pim-1 kinase. J Biol Chem 2005;280:6130-7
17. Jacobs MD, Black J, Futer O, et al. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem 2005;280:13728-34
18. Merkel AL, Meggers E, Ocker M. PIM1 kinase as a target for cancer therapy. Expert Opin Investig Drugs 2012;21:425-36
19. Morwick T. Pim kinase inhibitors: A survey of the patent literature. Expert Opin Ther Pat 2010;20:193-212
20. Gomez-Abad C, Pisonero H, Blanco-Aparicio C, et al. PIM as a rational target for B-cell lymphomas. CNIO Frontiers Meetings; 8 - 10 March 2010; Molecular Cancer Therapeutics 22. Centro Nacional de Investigaciones Oncologicas (CNIO). Tricyclic compounds for use as kinase inhibitors. WO004984; 2013
21. Centro Nacional de Investigaciones Oncologicas (CNIO). Triazolo [4, 5 - b] pyridin derivatives. WO101644; 2011
22. Centro Nacional de Investigaciones Oncologicas (CNIO). Tricyclic heterocyclic compounds as kinase inhibitors. WO005041; 2013
23. Centro Nacional de Investigaciones Oncologicas (CNIO). Imidazopyridazines for use as protein kinase inhibitors. WO060197; 2009
24. Centro Nacional de Investigaciones Oncologicas (CNIO). Aminoimidazolothiadiazoles for use as protein or lipid kinase inhibitors. WO020215; 2012
25. Centro Nacional de Investigaciones Oncologicas (CNIO). New compounds. WO005057; 2013
26. Centro Nacional de Investigaciones Oncologicas (CNIO). 6, 7-Ring-fused triazolo [4,3 - b] pyridazine derivatives as PIM inhibitors. WO098387; 2012
27. Cylene Pharmaceuticals, Inc. Pharmaceutically useful heterocyclesubstituted lactams. US0071115; 2011
28. Cylene Pharmaceuticals, Inc. Tricyclic compounds and pharmaceutical uses thereof. US0065712; 2011
29. Cylene Pharmaceuticals, Inc. Protein kinase modulators. US8168651; 2012
30. Cylene Pharmaceuticals, Inc. Novel protein kinase modulators. US0065698; 2011
31. Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors. US0152240; 2011
32. Cylene Pharmaceuticals, Inc. US0071115A1; 2011
33. Supergen, Inc. Imidazo[1,2-beta] pyridazine and pyrazolo[1,5-Alpha] pyrimidine derivatives and their use as protein kinase inhibitors. US7750007; 2010
34. Array Biopharma, Inc. Triazolopyridine compounds as PIM kinase inhibitors. WO022076; 2010
35. Array Biopharma, Inc. Triazolopyridine compounds as PIM kinase inhibitors. WO022081; 2010
36. Pastor J, Oyarzabal J, Saluste G, et al. Hit to lead evaluation of 1,2,3-Triazolo [4,5-b]pyridines as PIM kinase inhibitors. Bioorg Med Chem Lett 2012;22:1591-7
37. AstraZeneca AB. Chemical compounds 251. WO001169; 2010
38. Beharry Z, Zemskova M, Mahajan S, et al. Novel benzylidene-Thiazolidine- 2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther 2009;8:1473-83
39. Keeton E, Palakurthi S, Alimzhanov M, et al. 1540 AZD1208, a novel, potent and selective pan pim kinase inhibitor, demonstrates efficacy in models of acute myeloid leukemia. 53rd ASH Annual Meeting & Exposition; 10 - 13 December 2011
40. Centre National De La Recherche Scientifique (CNRS). 7-Substituted indirubin-3'oximes and their applications. US0331327; 2010
41. Cooley LLP. Rhodanines and related heterocycles as kinase inhibitors. US0331315; 2010
42. Cooley LLP. Pyrazolopyrimidines and related heterocycles as kinase inhibitors. US0331314; 2010
43. Cooley LLP. Novel protein kinase modulators. US0298302; 2010
44. Novartis AG. PIM kinase inhibitors and methods of their use. WO109576; 2009
45. Novartis AG. Cyclic ether compounds useful as kinase inhibitors. WO004217; 2012
46. Novartis AG. Heterocyclic PIM-kinase inhibitors. WO026122; 2010
47. Novartis AG. Bicyclic kinase inhibitors. WO026121; 2010
48. Novartis Institutes for BioMedical Research, Inc. PIM kinase inhibitors and methods of their use. US8168794; 2012
49. Novartis Institutes for BioMedical Research, Inc. Kinase inhibitors and methods of their use. US8329732; 2012
50. Nerviano Medical Sciences. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors. WO101032; 2012
51. Nerviano Medical Sciences. Pyrazolylpyrimidine derivatives as kinase inhibitors. WO139930; 2012
52. Nerviano Medical Sciences. Substituted pyrazolo-quinazoline derivatives as kinase inhibitors. WO080990; 2012
53. Morrison & Foerster LLP. Protein kinase modulators. US0239859; 2009
54. Morrison & Foerster LLP. Methods of treating disorders associated with protein kinase CK2 activity. US0267753; 2010
55. Morrison & Foerster LLP. Oxindole compounds. US0041635; 2010
56. Eli Lilly & Co. Protein kinase inhibitors. US7855211; 2010
57. F. Hoffmann-La Roche AG. Pyrazolo [3,4-c]pyridine compounds and methods of use. WO024002; 2013
58. Jasco pharmaceuticals LLC. Aminopyrimidine kinase inhibitors. US0152235; 2011
59. Carmen MB. PIM2 inhibitor as a targeted therapy for the treatment of multiple myeloma patients with specific genetic signatures. AACR Annual Meeting; 7 April 2013; Jasco Pharmaceuticals, LLC & Roswell Park Cancer Institute, Buffalo, NY 62. Macquarie University. Synthesis of ageladine a and analogs thereof. WO152584; 2009
60. Sanofi. Azaindole derivatives, their preparation and their therapeutic application. WO075613; 2011
61. Selvita SP. US0112091A1; 2011
62. Sygnis Bioscience. WO057784A1; 2011
63. Temple University. WO166586A1; 2012
64. Theravalues Corp. US8053461B2
65. Hashimoto T. Drug discovery business. Pim-1&3 inhibitors. Theravalues Corp. Tokyo: Japan; 2011
66. Tolero Pharmaceuticals, Inc. WO013188A1; 2013
67. Anderson D. Acquires drug development assets from astex pharmaceuticals. Tolero Pharmaceuticals, Inc., Salt Lake City, Utah; 2012
68. Holder S, Zemskova M, Zhang C, et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 2007;6:163-72
69. Xia Z, Knaak C, Ma J, et al. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 2009;52:74-86
70. Nishiguchi GA, Atallah G, Bellamacina C, et al. Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases. Bioorg Med Chem Lett 2011;21:6366-9
71. Lin YW, Beharry ZM, Hill EG, et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/ lymphoma. Blood 2010;115:824-33
72. Tsuganezawa K, Watanabe H, Parker L, et al. A novel Pim-1 kinase inhibitor targeting residues that bind the substrate peptide. J Mol Biol 2012;417:240-52
73. Baron BW, Anastasi J, Hyjek EM, et al. PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas. Proc Natl Acad Sci USA 2012;109:5735-9
74. An N, Kraft AS, Kang Y. Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. J Hematol Oncol 2013;6:12
75. Tarantul VZ. Transgenic mice as an in vivo model of lymphomagenesis. Int Rev Cytol 2004;236:123-80
76. Dakin LA, Block MH, Chen H, et al. Discovery of novel benzylidene-1,3- Thiazolidine-2,4-diones as potent and selective inhibitors of the PIM1, PIM2, and PIM3 protein kinases. Bioorg Med Chem Lett 2012;22:4599-604
77. Qian KC, Studts J, Wang L, et al. Expression, purification, crystallization and preliminary crystallographic analysis of human Pim-1 kinase. Acta Crystallogr Sect F Struct Biol Cryst Commun 2005;61:96-9
78. Kumar A, Mandiyan V, Suzuki Y, et al. Crystal structures of proto-oncogene kinase Pim1: A target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol 2005;348:183-93
79. Bullock AN, Debreczeni J, Amos AL, et al. Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 2005;280:41675-82
80. Cheney IW, Yan S, Appleby T, et al. Identification and structure-Activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 2007;17:1679-83
81. Maksimoska J, Williams DS, Atilla-Gokcumen GE, et al. Similar biological activities of two isostructural ruthenium and osmium complexes. E Chem Eur J 2008;14:4816-22
82. Qian K, Wang L, Cywin CL, et al. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. J Med Chem 2009;52:1814-27
83. Akue-Gedu R, Rossignol E, Azzaro S, et al. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. J Med Chem 2009;52:6369-81